Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors
- 796 Downloads
No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable CUP patients (A: serous peritoneal carcinomatosis n = 14, B: axillary adenocarcinoma n = 8, C: upper squamous cervical adenopathy n = 18) by means of a 64-microRNA assay. Subsequently, we profiled the expression of 733 microRNAs (miRs) in the CUP cases and compared results with metastases from 20 ovarian carcinomas, 10 breast adenocarcinomas, 20 squamous head neck or lung tumors. In the Peritoneal CUP versus Ovarian (Known Primary Metastases) KPM comparison, a total of 12 miR were significantly differentially expressed: higher than twofold expression difference in CUP was seen only for miR-513a-5p (3.7-fold upregulated) and miR-483-5p (2.5-fold upregulated), while miR-708 exhibited a twofold downregulation. In the Breast CUP versus Breast KPM comparison, only miR-29c that were downregulated in CUP by 2.7-fold satisfied the FDR threshold. miR-30e and miR-27b, downregulated in ovarian CUPs versus KPMs, were also non-significantly downregulated in breast CUP by 2.0- and 1.4-fold respectively. Six miRs, which belong to the 17–92 oncocluster showed a trend of upregulation in Breast CUP versus Breast KPM cases. A CUP signature remains elusive.
KeywordsCancer of unknown primary MicroRNA Gene expression
Conflicts of interest
George Pentheroudakis, Dimitrios Krikelis, Vassiliki Kotoula, Vassiliki Malamou-Mitsi, George Fountzilas, Nicholas Pavlidis have no conflicts of interest to disclose. Yael Spector, Eti Meiri, Mats Sanden, Hila Benjamin and Ranit Aharonov are employees of Rosetta Genomics. YS, EM, HB and RH hold stock options of the company, which develops miR based diagnostic products and may stand to gain by publications of these findings. Each of the authors is willing to complete an individual, electronic conflict-of-interest form.
- 14.Joh JE, Esposito NN, Kiluk JV et al (2011) The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 16:1520–1526PubMedCrossRefGoogle Scholar
- 22.Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R (2012) Molecular gene expression profiling to predict the tissue of Origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute. J Clin Oncol doi: 10.1200/JCO2012.43.3755
- 37.Fizazi K, Greco FA, Pavlidis N et al. (2011) Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi64–68Google Scholar